勃起功能障碍治疗市场：2025-2032 年全球预测（按销售模式、治疗时间、分销管道、剂量强度和患者年龄层）

预计到 2032 年，勃起功能障碍药物市场规模将成长至 46.7 亿美元，复合年增长率为 7.63%。

主要市场统计数据
基准年2024年	25.9亿美元
预计2025年	27.9亿美元
预测年份：2032年	46.7亿美元
复合年增长率（%）	7.63%

勃起功能障碍药物的研发过程很复杂，涉及临床实践、不断变化的患者期​​望以及不断变化的支付方动态。近期趋势，包括药理学的进展、数位医疗整合以及病人参与模式，正在全面重塑临床医生和生物技术公司在治疗开发和商业化方面的方式。同时，减少污名化的努力和广泛的宣传宣传活动正在鼓励更多患者寻求治疗，远端医疗和线上药局管道也为诊断和治疗的启动提供了新的途径。

在此背景下，相关人员需要整合临床证据、监管趋势、不断变化的分销管道和病患行为的可操作情报。临床医生在推荐治疗方法时，需要平衡疗效、耐受性和便利性，而药物开发商则必须在影响处方模式的品牌药和学名药的竞争格局中寻找出路。付款人和医疗系统正在调整覆盖框架和利用管理，製造商也面临压力，需要透过长期安全性和生活品质数据来证明药物除了缓解症状之外的其他价值。

本执行摘要概括了治疗方法、通路、管理考虑因素和人口需求驱动因素方面的关键主题发展和决策见解，旨在帮助行业领导者、临床项目经理和商业战略家了解影响当前和近期勃起功能障碍治疗前景的关键力量，为后续战略考虑提供简明而全面的基础。

药物创新、数位化医疗服务和付款人监督如何融合，重新定义勃起功能障碍治疗的成功率和患者可及性

在药理学创新、数位化医疗服务以及患者期望不断变化等因素的推动下，勃起功能障碍治疗领域正在经历一场变革。新的製剂和给药系统，以及对耐受性和起效时间的重新重视，正在拓宽泌尿系统和基层医疗的治疗对话。同时，数位健康平台和远端医疗正在减少问诊和处方环节的摩擦，缩短许多患者的治疗开始时间。

同时，随着成熟品牌疗法面临学名药药的衝击，以及各公司寻求强调便利性、独特配方和患者支持服务的生命週期策略，竞争动态日益加剧。为此，支付方正在完善覆盖标准和事先核准框架，从而在商业规划中更加重视可靠的真实世界证据和健康经济学原理。这些相互关联的趋势迫使製造商将临床开发与可操作的终点、患者报告结果和依从性支持措施相结合。

监管和报销格局也不断调整，显示出对性健康产品比较有效性数据和上市后安全监测的兴趣。加上患者群体更加知情，寻求谨慎、便捷、有效的解决方案，这进一步凸显了对一种将临床差异化与卓越患者体验相结合的整合方法的需求。最终，药理学创新、数位化可及性和付款人督导的整合正在重新定义治疗领域的成功指标，并推动相关人员采取更灵活、更主导的策略。

评估 2025 年关税环境对勃起功能障碍药物的连续性、定价和病患取得途径的营运、采购和分销影响

2025年新关税和贸易政策的出台，为整个医药价值链上的製造商、经销商和药房网络带来了一系列营运和供应链的考量。不断变化的关税结构正在影响原料药和成品药的筹资策略，促使一些公司重新评估供应商多元化、库存策略和区域製造地。这促使一些公司加快近岸外包谈判和应急计划，以保持供应的连续性并保护其利润率。

在分销层面，与关税相关的成本压力促使相关人员重新评估价格透明度以及与批发商和药房合作伙伴的合约条款。这些压力也促使製造商进行更严格的服务成本分析，重点是优化物流网络并利用临床可行的大量采购。同时，线上药局等数位管道已成为维护患者取得药品的重点，因为它们能够缓解某些分销摩擦，并满足患者对谨慎便捷的履约的偏好。

除了营运调整之外，2025年累积关税的影响还要求商业和市场进入团队之间开展新的对话，以确保产品价格合理并符合当地报销政策。追求全球策略的製造商正在加强监管、供应链和商业部门之间的协作，以预测跨境影响并制定维持治疗可及性的定价策略。因此，对于寻求应对关税相关波动并同时确保患者获得勃起功能障碍药物的公司而言，供应弹性、灵活采购和与利益相关相关人员的协作已成为核心优先事项。

细分洞察，包括销售模式、治疗时间、分销管道、剂量强度和患者人口统计数据，指导有针对性的商业化

特定细分市场的动态揭示了产品模式、疗程、通路、给药方案和患者人口统计方面存在的差异化商业机会和挑战。考虑到销售模式的差异，品牌产品继续透过附加价值服务、临床证据包和有针对性的患者援助计划寻求差异化，而学名药在价格和可用性方面展开竞争，对处方和报销管道施加压力。在疗程方面，长期方案面临依从性和安全性监测的考量，这推动了对病患参与工具和结果追踪的需求，而短期疗法则强调快速起效、便利性和最小化的互动负担。

分销通路细分凸显了线上履约作为传统医院和零售药局网路补充日益增长的重要性。数位管道提供便利性和保密性，强烈契合寻求谨慎护理的患者的需求；而医院药房对于注重合併症和专科医生监督的整合护理路径而言，仍然至关重要。研究剂量强度偏好发现，25毫克、50毫克和100毫克的剂量选择对于根据疗效和耐受性调整剂量的处方医生而言具有战略意义，因为不同的临床表现和合併症情况会有不同的需求。 40岁以下的患者优先考虑便利性和较少的副作用，40-60岁的患者则在疗效与生活方式影响和伴侣考虑之间取得平衡，而60岁及以上的患者则优先考虑安全性、併发症管理以及与合併用药的相互作用。

整合这些细分视角，使相关人员能够制定差异化的产品定位、商业策略和病患支援机制，以符合处方医师的决策和病患的偏好。例如，将品牌价值提案与强大的远端保健医疗依从性服务相结合，可以改善长期治疗效果，同时确保线上药局管道的竞争性定价和合理的可及性，可以扩大短期干预措施的规模。基于细分的策略对于优化不同患者群体和分销环境中的治疗吸收、依从性和治疗成功率至关重要。

美洲、欧洲、中东和非洲以及亚太地区在获取药物、监管重点和病患行为方面的区域差异将影响客製化的市场方法

区域动态揭示了临床实践模式、监管重点和患者行为的显着差异，这些差异会影响治疗方法和商业策略。在美洲，成熟的医疗保健生态系统将先进的数位化应用与成熟的专科药房和零售药房网路相结合，创造出远端医疗、患者直接互动和付款人谈判在患者获取和保留中发挥核心作用的环境。在美洲，整合照护路径和价值展示通常是处方集定位的优先事项，这更凸显了真实世界证据和健康结果数据的重要性。

欧洲、中东和非洲地区 (EMEA) 在法律规范、报销制度和医疗保健可近性方面表现出相当大的差异性。西方市场往往注重比较有效性和成本效益评估，而中东和北非市场则优先考虑扩大供应管道和提高供应可靠性。跨境采购动态和多样化的分销基础设施需要打入市场策略，并采用本地化的证据生成和合作模式，以满足区域付款人的期望和物流限制。

亚太地区的医疗保健成熟度和对性健康的文化观念差异巨大，许多都市区正在快速数位化，从而推动远端医疗和网路药局解决方案的普及。该地区各国的监管途径和定价机制各不相同，因此需要采取细緻入微的商业化方法，充分考虑当地的处方行为、报销方式以及某些司法管辖区中非处方药的作用。在所有地区，将临床讯息与文化敏感度、监管要求和分销现实相结合，对于实现临床效果和永续的商业性绩效至关重要。

领先的製药公司如何结合临床差异化、全通路参与和供应链弹性来加强其治疗定位

为了保持竞争优势，勃起功能障碍治疗领域的主要企业正在努力将临床差异化、生命週期管理和通路优化相结合。一些公司专注于透过整合支援计划、数位化依从性工具以及连接临床护理和便利履约选项的伙伴关係关係来改善病人历程。另一些公司则优先考虑配方创新和新型给药系统，以逐步改善起效时间、耐受性和易用性，从而创造与处方医生产生共鸣的独特临床方案。

在商业性，企业正在投资全通路互动策略，以满足患者对个人化和快速获取服务的偏好，同时与专科医生和基层医疗医生保持稳固的关係。随着企业寻求满足数位化患者需求，与远端医疗提供者和获得许可的线上药局建立策略合作伙伴关係变得越来越重要。同时，一些企业正在优先考虑供应链的韧性和区域製造的灵活性，以减轻贸易政策的干扰，并确保跨不同分销网络的持续供应。

在证据方面，重点是收集可操作的临床数据和患者报告结果，以证实关于生活品质和长期安全性的主张。拥有强大临床组合、可扩展的患者支援和扩充性管道策略的公司能够快速响应不断变化的付款方需求和患者期望，从而增强其在多种治疗环境中维持患者接受度和依从性的能力。

高阶主管必须将证据生成、全通路访问、供应弹性和以人口为中心的定位结合起来，以保持治疗和商业性的成功，这是一项战略要务

为了最大限度地提高治疗效果和组织韧性，行业领导者应优先考虑一系列切实可行的措施，以协调临床开发、商业性执行和患者可及性目标。首先，将真实世界证据生成和患者报告结果收集纳入核准后项目，以支持与付款方的讨论，并展示除症状控制之外的长期价值。这些依证将支持更具吸引力的价值提案，并有助于确保在不同的报销环境中获得良好的覆盖。

第二，投资全通路分销和病人参与策略，将传统药局履约与远端保健伙伴关係以及线上药局配送结合。这种协调一致的方案使患者能够谨慎便捷地获取药品，并在需要时获得临床医生的监督。第三，多样化采购和生产策略，以减少关税带来的中断风险​​，并维持供应的连续性。近岸外包、多方采购和策略性库存缓衝可以降低营运风险并保持商业性发展动能。

第四，将产品定位和剂量选择与人口统计和临床细分群体相结合，确保讯息在40岁以下、40-60岁和60岁以上的患者群体中产生共鸣，并在25毫克、50毫克和100毫克剂量选择之间为处方医生提供明确的指导。最后，透过将临床终点与卫生经济优先事项相结合，并提供支持依从性和合理用药的计划，促进与付款人和卫生系统的合作。执行这些优先事项需要临床、监管、商业和供应链团队之间的跨职能协作，将洞察转化为可衡量的成果。

详细介绍文献综合、相关人员访谈和跨細項分析的调查方法概述提供了可靠、可行的治疗见解

这项二次研究结合了严谨的二次资讯分析、相关人员访谈和结构化证据审查，旨在为临床、商业和营运决策者提供切实可行的见解。二次分析涵盖同行评审的临床文献、监管资讯、已发表的治疗指南以及公开的政策文件，旨在建立科学和监管背景的基础。这些资讯来源被用来绘製主要治疗机构的治疗范例、安全考量以及符合指引的实务。

为了补充文献综述，我们与包括临床医生、药房负责人、付款人和数位医疗合作伙伴在内的各类相关人员进行了定性访谈，以了解处方行为、病人参与和分销渠道动态的实际观点。访谈结果与通路成长模式的观察资料以及公司公开发布的倡议进行了交叉比对，从而对策略重点和营运约束做出均衡的解读。

分析方法包括跨细分综合法，用于检验销售模式、疗程、分销管道、剂量和患者人口统计数据之间的相互作用，以及基于情境的近期关税变化对供应链影响的评估。在整个研究过程中，我们运用资料完整性检查和资讯来源三角测量，以最大程度地减少偏差，并确保结论能反映证据流中趋同的讯号。本调查方法强调透明度、可重复性和实践相关性，以帮助相关人员将洞察应用于其策略和营运。

结论：强调需要基于证据的临床叙述、管道灵活性和以细分为重点的商业化，以实现持续的患者和商业性成果

当前勃起功能障碍领域的竞争格局呈现以下特点：患者参与度不断提升，对便利性和自主性要求日益提高，以及品牌药和非专利之间的竞争日益激烈。这些动态凸显了整合策略的必要性，将临床差异化、以患者为中心的可及性途径和富有韧性的营运模式融为一体。在可操作的临床终点和患者报告结果方面，提供强有力的证据将变得越来越重要，以确保良好的报销结果并维护处方医生的信心。

此外，细分市场的商业化能够适应分销模式、疗程、通路偏好、给药方案和年龄层的差异，从而实现更精准的定位，并提高治疗依从性和满意度。美洲、欧洲、中东和非洲以及亚太地区的区域差异进一步要求采取独特的方法，以尊重当地的监管要求、文化观念和分销现状。最后，多元化采购和数位通路伙伴关係等营运要素对于维持市场准入和应对贸易动态带来的成本压力至关重要。

总之，结合实证临床叙述、灵活分销架构和以客户为中心的参与模式的组织将最有能力应对不断变化的环境并实现持续的患者和商业性成果。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 非处方低剂量Sildenafil和他达拉非製剂的普及提高了市场准入
• 将远端医疗平台与直接面向消费者的勃起功能障碍处方笺和数位健康监测结合
• 人们越来越关注透过基因分析实现个人化医疗，以优化勃起功能障碍药物的疗效
• 开发新型一氧化氮供体化合物和替代给药方法，如舌下膜和鼻喷雾剂
• 品牌 PDE5 抑制剂的专利到期导致学名药竞争加剧，价格下降。
• 人们对将干细胞疗法与传统 ED 药物结合的再生疗法越来越感兴趣
• 扩大治疗勃起功能障碍的适应症，包括肺动脉高压和良性前列腺增生等合併症
• 生活方式倡议与药物治疗相结合对患者依从性和长期结果的影响
• 除了传统的 PDE5 抑制剂外，还出现了针对勃起功能障碍替代途径的胜肽类疗法
• 安全性更高、药物交互作用最小化的下一代PDE5抑制剂获得监管部门核准

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：勃起功能障碍治疗市场（依销售模式）

• 品牌
• 非专利的

第九章勃起功能障碍治疗市场（依治疗期）

• 长期
• 短期

第 10 章勃起功能障碍药物市场（依分销管道）

• 医院药房
• 网路药局
• 零售药局

第 11 章。勃起功能障碍药物市场（按剂量强度）

• 100mg
• 25mg
• 50mg

第 12 章。勃起功能障碍治疗市场（依患者年龄层）

• 40至60岁
• 超过60年
• 40岁以下

第 13 章勃起功能障碍药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 14 章勃起功能障碍药物市场（按类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 15 章。 勃起功能障碍药物市场（按国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited

The Erectile Dysfunction Drugs Market is projected to grow by USD 4.67 billion at a CAGR of 7.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.59 billion
Estimated Year [2025]	USD 2.79 billion
Forecast Year [2032]	USD 4.67 billion
CAGR (%)	7.63%

Erectile dysfunction therapeutics occupy a complex intersection of clinical practice, evolving patient expectations, and shifting payer dynamics. Recent years have seen advances in pharmacology, digital health integration, and patient engagement models that collectively reshape how clinicians and biotech companies approach treatment development and commercialization. Simultaneously, stigma reduction efforts and broader awareness campaigns have driven more patients to seek care, while telemedicine and online pharmacy channels have offered new pathways for diagnosis and treatment initiation.

Against this backdrop, stakeholders require actionable intelligence that synthesizes clinical evidence, regulatory trends, distribution channel evolution, and patient behavior. Clinicians increasingly balance efficacy, tolerability, and convenience when recommending therapies, while pharmaceutical developers must navigate a more crowded competitive landscape with both branded and generic options influencing prescribing patterns. Payers and health systems are adjusting coverage frameworks and utilization management, prompting manufacturers to demonstrate value beyond symptomatic relief through long-term safety and quality-of-life data.

This executive summary condenses critical thematic developments and decision-relevant insights across therapy modalities, distribution pathways, dosing considerations, and demographic demand drivers. It aims to orient industry leaders, clinical program managers, and commercial strategists to the principal forces shaping the erectile dysfunction therapeutic environment today and near term, providing a concise yet comprehensive foundation for subsequent strategic deliberations.

How pharmacologic innovation, digital care delivery, and payer scrutiny are converging to redefine therapeutic success and patient access in erectile dysfunction care

The erectile dysfunction therapeutic landscape is undergoing transformative shifts driven by innovation in pharmacology, digital care delivery, and evolving patient expectations. Novel formulations and delivery systems, alongside renewed emphasis on tolerability and onset of action, have broadened therapeutic conversations within urology and primary care. Meanwhile, digital health platforms and telemedicine have reduced friction in obtaining consultation and prescriptions, accelerating time to treatment initiation for many patients.

Concurrently, competitive dynamics are intensifying as established branded therapies face generic entrants and as companies explore lifecycle strategies that emphasize convenience, proprietary formulations, and patient support services. Payers are responding by refining coverage criteria and prior authorization frameworks, which has elevated the importance of robust real-world evidence and health-economic arguments in commercial planning. These interconnected trends have pushed manufacturers to align clinical development with pragmatic endpoints, patient-reported outcomes, and adherence-support initiatives.

Regulatory and reimbursement environments are also adapting, with agencies showing interest in comparative effectiveness data and post-marketing safety surveillance for sexual health products. This, coupled with a more informed patient population seeking discreet, convenient, and effective solutions, reinforces the need for integrated approaches that combine clinical differentiation with superior patient experiences. Ultimately, the confluence of pharmacological innovation, digital access, and payer scrutiny is redefining success metrics in the therapeutic area and prompting stakeholders to adopt more agile, evidence-driven strategies.

Assessing the operational, sourcing, and distribution implications of the 2025 tariff environment on continuity, pricing, and patient access for erectile dysfunction therapeutics

The introduction of new tariff measures and trade policies in 2025 has introduced a set of operational and supply-chain considerations for manufacturers, distributors, and pharmacy networks across the pharmaceutical value chain. Changes in tariff structures have influenced sourcing strategies for active pharmaceutical ingredients and finished dosage forms, encouraging some companies to re-evaluate supplier diversification, inventory strategies, and regional manufacturing footprints. In response, several organizations have accelerated nearshoring discussions and contingency planning to maintain supply continuity and protect margin profiles.

At the distribution level, tariff-related cost pressures have led stakeholders to reassess pricing transparency and contractual terms with wholesalers and pharmacy partners. These pressures have also prompted more rigorous cost-to-serve analyses by manufacturers, with an emphasis on optimizing logistics networks and leveraging bulk procurement where clinically feasible. In parallel, digital channels such as online pharmacies have become focal points for preserving patient access, given their capacity to mitigate certain distribution frictions and meet patient preferences for discreet, convenient fulfillment.

Beyond operational adjustments, the cumulative tariff impacts of 2025 have prompted renewed dialogue between commercial teams and market access functions to ensure product affordability and adherence to local reimbursement policies. Manufacturers pursuing global strategies have increased coordination between regulatory, supply-chain, and commercial teams to anticipate cross-border implications and to design pricing strategies that preserve therapeutic accessibility. As a result, supply resilience, flexible sourcing, and coordinated stakeholder engagement have emerged as central priorities for entities seeking to manage tariff-related volatility while sustaining patient access to erectile dysfunction therapies.

Segment-driven insights across sales models, treatment durations, distribution channels, dosage strengths, and patient age cohorts to guide targeted commercialization

Segment-specific dynamics reveal differentiated opportunities and challenges that vary by product model, treatment duration, distribution pathway, dosage strength, and patient age cohort. When considering sales model distinctions, branded products continue to pursue differentiation through value-added services, clinical evidence packages, and targeted patient support programs, while generic alternatives compete on price and accessibility, exerting pressure across prescribing and reimbursement channels. In the domain of treatment duration, long-term regimens face adherence and safety monitoring considerations that drive demand for patient engagement tools and outcome tracking, whereas short-term therapies emphasize rapid onset, convenience, and minimal interaction burden.

Distribution channel segmentation highlights the growing significance of online pharmacy fulfillment as a complement to traditional hospital pharmacy and retail pharmacy networks; digital channels offer convenience and confidentiality that resonate strongly with patients seeking discreet treatment, while hospital pharmacies remain critical for integrated care pathways where comorbidities and specialist oversight are paramount. Examination of dosage strength preferences indicates that varying needs across clinical presentations and comorbidity profiles make 25 mg, 50 mg, and 100 mg options strategically important for prescribers who tailor dosing to efficacy and tolerability considerations. Age-based segmentation underscores distinct motivational and clinical factors: individuals under 40 often prioritize convenience and minimal side effects, patients aged 40-60 balance efficacy with lifestyle impact and partner considerations, and those 60 and older typically emphasize safety, comorbidity management, and interactions with concomitant medications.

Integrating these segmentation lenses allows stakeholders to craft differentiated product positioning, commercial tactics, and patient support mechanisms that align with prescriber decision-making and patient preferences. For example, combining branded value propositions with robust telehealth-enabled adherence services may enhance long-term therapy outcomes, while ensuring competitive pricing and streamlined access in online pharmacy channels can expand reach for short-duration interventions. Taken together, segmentation-informed strategies are essential to optimize uptake, adherence, and therapeutic success across diverse patient cohorts and distribution environments.

Regional differentiation in access, regulatory emphasis, and patient behavior across the Americas, Europe Middle East & Africa, and Asia-Pacific influencing tailored market approaches

Regional dynamics present notable variations in clinical practice patterns, regulatory emphasis, and patient behavior that influence therapeutic approaches and commercial tactics. In the Americas, a mature healthcare ecosystem combines high digital adoption with established specialty and retail pharmacy networks, creating an environment where telemedicine, direct-to-patient engagement, and payer negotiation play central roles in patient acquisition and retention. The Americas often prioritize integrated care pathways and value demonstration for formulary positioning, which amplifies the importance of real-world evidence and health outcomes data.

The Europe, Middle East & Africa region exhibits considerable heterogeneity in regulatory frameworks, reimbursement systems, and healthcare access. Western European markets tend to emphasize comparative effectiveness and cost-effectiveness assessments, whereas several Middle Eastern and African markets prioritize access expansion and supply reliability. Cross-border procurement dynamics and varying distribution infrastructures require tailored market entry strategies, with localized evidence generation and partnership models that address regional payer expectations and logistical constraints.

Asia-Pacific encompasses a broad spectrum of healthcare maturation levels and cultural attitudes toward sexual health, with rapid digital adoption in many urban centers facilitating telehealth and e-pharmacy solutions. Countries within the region vary in regulatory pathways and pricing mechanisms, necessitating a nuanced approach to commercialization that considers local prescribing behaviors, reimbursement levers, and the role of over-the-counter availability in some jurisdictions. Across all regions, aligning clinical messaging with cultural sensitivities, regulatory requirements, and distribution realities is essential to achieve both clinical impact and sustainable commercial performance.

How leading pharmaceutical and product companies are combining clinical differentiation, omnichannel engagement, and supply-chain resilience to strengthen therapeutic positioning

Leading companies within the erectile dysfunction therapeutic space are pursuing a combination of clinical differentiation, lifecycle management, and channel optimization to sustain competitive positioning. Several firms focus on enhancing the patient journey through integrated support programs, digital adherence tools, and partnerships that bridge clinical care with convenient fulfillment options. Others emphasize formulation innovations or novel delivery systems that seek incremental improvements in onset of action, tolerability, or ease of use, thereby creating distinct clinical narratives that resonate with prescribers.

Commercially, companies are investing in omnichannel engagement strategies that align with patient preferences for discrete, fast access while maintaining strong relationships with specialist and primary care prescribers. Strategic alliances with telehealth providers and licensed online pharmacies have become increasingly important as firms aim to capture demand from digitally enabled patients. At the same time, some organizations prioritize supply-chain resilience and regional manufacturing flexibility to mitigate trade policy disruptions and ensure consistent availability across diverse distribution networks.

On the evidence front, there is a discernible emphasis on collecting pragmatic clinical data and patient-reported outcomes to substantiate claims around quality of life and long-term safety. Companies that combine robust clinical portfolios with scalable patient support and flexible channel strategies are positioned to respond swiftly to evolving payer requirements and shifting patient expectations, thereby strengthening their ability to sustain uptake and adherence across multiple treatment settings.

Strategic imperatives for executives to align evidence generation, omnichannel access, supply resilience, and demographic-focused positioning to sustain therapeutic and commercial success

Industry leaders should prioritize a set of actionable steps that align clinical development, commercial execution, and patient access objectives to maximize therapeutic impact and organizational resilience. First, integrate real-world evidence generation and patient-reported outcome collection into post-approval programs to support payer discussions and to demonstrate long-term value beyond symptom control. This evidence base will underpin more persuasive value propositions and help secure favorable coverage terms in diverse reimbursement environments.

Second, invest in omnichannel distribution and patient engagement strategies that combine traditional pharmacy relationships with telehealth partnerships and online pharmacy fulfillment. A coordinated approach ensures patients can access therapies discreetly and conveniently while maintaining clinician oversight where necessary. Third, diversify sourcing and manufacturing strategies to reduce exposure to tariff-driven disruptions and to maintain supply continuity. Nearshoring, multi-sourcing, and strategic inventory buffers can reduce operational risk and preserve commercial momentum.

Fourth, tailor product positioning and dosing options to demographic and clinical segments, ensuring that messaging resonates with under 40, 40-60, and 60+ patient cohorts and that prescribers have clear guidance on dose selection across 25 mg, 50 mg, and 100 mg options. Finally, cultivate collaborative relationships with payers and health systems by aligning clinical endpoints with health-economic priorities and by offering programs that support adherence and appropriate utilization. Executing on these priorities will require cross-functional alignment among clinical, regulatory, commercial, and supply-chain teams to translate insights into measurable outcomes.

Methodological overview detailing literature synthesis, stakeholder interviews, and cross-segmentation analysis to ensure robust and actionable therapeutic insights

This research synthesis combines rigorous secondary-source analysis, stakeholder interviews, and structured evidence review to produce actionable insights relevant to clinical, commercial, and operational decision makers. Secondary analysis encompassed peer-reviewed clinical literature, regulatory communications, published treatment guidelines, and publicly available policy documents to establish a foundation of scientific and regulatory context. These sources were used to map treatment paradigms, safety considerations, and guideline-directed practice across major therapeutic settings.

To complement the literature review, qualitative interviews were conducted with a diverse set of stakeholders including clinicians, pharmacy leaders, payers, and digital health partners to capture frontline perspectives on prescribing behavior, patient engagement, and distribution channel dynamics. Interview inputs were triangulated with observational data on channel growth patterns and with publicly reported corporate initiatives to ensure a balanced interpretation of strategic priorities and operational constraints.

Analytical methods included cross-segmentation synthesis to examine interactions between sales models, treatment durations, distribution channels, dosage strengths, and patient age cohorts, as well as scenario-based assessment of supply-chain impacts from recent tariff changes. Throughout the research process, data integrity checks and source triangulation were applied to minimize bias and to ensure that conclusions reflect convergent signals across evidence streams. The methodological approach emphasizes transparency, replicability, and practical relevance for stakeholders seeking to apply the insights to strategic planning and operational execution.

Conclusion emphasizing the need for evidence-driven clinical narratives, channel flexibility, and segmentation-focused commercialization to achieve sustained patient and commercial outcomes

The current therapeutic landscape for erectile dysfunction is characterized by expanding patient engagement avenues, heightened expectations for convenience and discretion, and intensifying commercial competition between branded and generic options. These dynamics underscore the need for integrated strategies that marry clinical differentiation with patient-centric access pathways and resilient operational models. Robust evidence generation, across both pragmatic clinical endpoints and patient-reported outcomes, will be increasingly important to secure favorable reimbursement outcomes and to sustain prescriber confidence.

Moreover, segmentation-aware commercialization-attuned to differences by sales model, treatment duration, channel preference, dosage strength, and age cohort-enables more precise targeting and higher likelihood of therapeutic adherence and satisfaction. Regional nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific further necessitate tailored approaches that respect local regulatory expectations, cultural attitudes, and distribution realities. Finally, operational imperatives such as diversified sourcing and digital channel partnerships will be central to maintaining access and managing cost pressures introduced by trade dynamics.

In sum, organizations that blend evidence-based clinical narratives, flexible distribution architectures, and customer-centric engagement models will be best positioned to navigate the evolving environment and to deliver sustained patient and commercial outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of over-the-counter low-dose sildenafil and tadalafil formulations boosting market accessibility
• 5.2. Integration of telemedicine platforms with direct-to-consumer erectile dysfunction prescriptions and digital health monitoring
• 5.3. Increasing focus on personalized medicine through genetic profiling for erectile dysfunction drug efficacy optimization
• 5.4. Development of novel nitric oxide donor compounds and alternative delivery methods like sublingual films and nasal sprays
• 5.5. Impact of patent expirations on branded PDE5 inhibitors fueling intensified generic competition and price erosion
• 5.6. Growing interest in regenerative therapies combining stem cell treatments with conventional ED pharmacotherapy
• 5.7. Expansion of erectile dysfunction treatment indications to address comorbid conditions like pulmonary hypertension and benign prostatic hyperplasia
• 5.8. Influence of lifestyle modification initiatives integrated with pharmacotherapy on patient adherence and long-term outcomes
• 5.9. Emergence of peptide-based therapeutics targeting alternative erectile pathways beyond conventional PDE5 inhibition
• 5.10. Regulatory approvals of next-generation PDE5 inhibitors with enhanced safety profiles and minimal drug interactions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Drugs Market, by Sales Model

• 8.1. Branded
• 8.2. Generic

9. Erectile Dysfunction Drugs Market, by Treatment Duration

• 9.1. Long-Term
• 9.2. Short-Term

10. Erectile Dysfunction Drugs Market, by Distribution Channel

• 10.1. Hospital Pharmacy
• 10.2. Online Pharmacy
• 10.3. Retail Pharmacy

11. Erectile Dysfunction Drugs Market, by Dosage Strength

• 11.1. 100 Mg
• 11.2. 25 Mg
• 11.3. 50 Mg

12. Erectile Dysfunction Drugs Market, by Patient Age Group

• 12.1. 40-60 Years
• 12.2. 60+ Years
• 12.3. Under 40 Years

13. Erectile Dysfunction Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Erectile Dysfunction Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Erectile Dysfunction Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Pfizer Inc.
  • 16.3.2. Eli Lilly and Company
  • 16.3.3. Bayer AG
  • 16.3.4. Teva Pharmaceutical Industries Ltd.
  • 16.3.5. Viatris Inc.
  • 16.3.6. Sandoz International GmbH
  • 16.3.7. Dr. Reddy's Laboratories Ltd.
  • 16.3.8. Sun Pharmaceutical Industries Ltd.
  • 16.3.9. Aurobindo Pharma Limited
  • 16.3.10. Cipla Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 97. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 99. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 107. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 110. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 112. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 114. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 116. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 119. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 122. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 123. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 124. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 126. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 128. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 130. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 143. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 155. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 158. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 160. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 162. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 164. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 166. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 167. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 170. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 171. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 172. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 173. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 174. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 175. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 176. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 177. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 178. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 182. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 184. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 186. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 188. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 190. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 196. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 197. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 198. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 199. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 202. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 203. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 204. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 208. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 209. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 210. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 211. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 213. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 214. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 215. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 220. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 221. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 222. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 223. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 224. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 225. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 226. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 227. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 228. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 229. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 232. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 233. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 234. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 235. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 238. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 239. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 240. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 241. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 244. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 245. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 246. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 247. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 249. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 250. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 251. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 252. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 253. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 256. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 257. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 258. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 259. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 260. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 261. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 262. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 263. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 264. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 268. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 269. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 270. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 271. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 274. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 275. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 276. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 277. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 278. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 279. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 280. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 281. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 282. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 283. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 284. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 285. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 286. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 287. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 288. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 289. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 290. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 291. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 294. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 295. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 296. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 297. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 298. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 299. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 300. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 301. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 302. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 303. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 304. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 305. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 306. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 307. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
• TABLE 308. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2032 (USD MILLION)
• TABLE 309. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 310. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2032 (USD MILLION)
• TABLE 311. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 312. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 313. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZ